RESEARCHER PROFILE (Filmed April 2024)
Associate Professor Jelena Rnjak-Kovacina
Graduate School of Biomedical Engineering
UNSW Sydney, Australia
Dr Jelena Rnjak-Kovacina is a Scientia Associate Professor and ARC Future Fellow leading a multidisciplinary group at the Graduate School of Biomedical Engineering, UNSW Sydney in Australia.
She completed her doctoral degree in Anthony Weiss’ lab at the University of Sydney and her postdoctoral training in David Kaplan’s group at Tufts University in Boston. She joined UNSW in 2014 where her research has been supported by funding from the Australian Research Council, the National Heart Foundation, the National Health & Medical Research Council, and NSW Health. She is the recipient of multiple awards, including most recently, the NSW Ministerial Award for Rising Stars in Cardiovascular Research and the Early Career Researcher of the Year (Physical Sciences) in the NSW Premier’s Prizes for Science & Engineering.
Her research interests are at the interface of biology and engineering, focusing on the development of biomimetic materials that direct cellular interactions for enhanced vascularisation and for the treatment of cardiovascular disease. In particular, she develops novel silk-based biomaterials and investigates how biomaterial properties translate to biological outcomes.
She is actively involved in the Australasian MedTech sector, including as Vice President of the Australasian Society for Biomaterials & Tissue Engineering (ASBTE), board member of the Australian Cardiovascular Alliance (ACvA) Bioengineering flagship, Fellow of the Tissue Engineering & Regenerative Medicine International Society, and through editorial roles for multiple journals. She is passionate about research training and communication.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
